alexa Cancer Pharmacogenomic Testing, Clinician Adoption And Patient Benefit
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Lynn Dressler
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.010
Abstract
Background: Cancer pharmacogenomics (caPGx) evaluates the genomic profiles of individuals and their tumors to predict response to treatment, including the potential to select which treatment or dose may be more effective with the least adverse side effects. Understanding the factors that influence clinician adoption of caPGx tests is important to promote timely and equitable patient benefit. Methods: Anonymous paper surveys, addressing oncologists perspective and knowledge of caPGx tests, factors influencing caPGx test adoption, and desire for PGx education, were distributed to oncologists in North Carolina, USA. Results: Although 98% indicated that PGx holds great promise in guiding the treatment of cancer patients, only 33% were comfortable with their knowledge or interpretation of caPGx test results. When asked about factors influencing use of specific caPGx tests (Oncotype Dx test), 26% indicated they used the test because it was FDA approved. This is concerning because the test is NOT FDA approved, nor does it currently require FDA approval. Perhaps even more concerning was the selection by 5% of respondents of a mammogram or a complete blood count (CBC) being a PGx test. Ninety-one percent of respondents were interested in learning more about caPGx. Summary: There is a desire and need for dissemination of accurate PGx information to oncologists in North Carolina. Development of tailored educational interventions should improve knowledge and use of caPGx tests to maximize opportunities for equitable patient benefit.
Biography
Lynn Dressler directs the Personalized Medicine program at Mission Health, a large tertiary care community hospital system in Western North Carolina. For 30 years, Dressler has worked in academic research, at the interface between the bench and bedside evaluating new markers to predict response to therapy. Her inter-disciplinary training spans translational research in pathology, oncology, health policy, bioethics and social science. During her 20 year tenure at the University of North Carolina, her laboratory conducted the research study that directly led to the FDA approval of the PathVYsion? HER2 FISH test, one of the first pharmacogenomics tests in breast cancer.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version